a Aim Ethnicity plays a modulating role in atorvastatin pharmacokinetics (PK), with Asian patients reported to have higher exposure compared with Caucasians. Therefore, it is difficult to safely extrapolate atorvastatin PK data and models across ethnic groups. This work aims to develop a population PK model for atorvastatin and its pharmacologically active metabolites specifically for the Japanese population. Subsequently, it aimed to identify genetic polymorphisms affecting atorvastatin PK in this population.
Introduction
Atorvastatin belongs to the class of HMG-CoA reductase inhibitors (statins) and is currently one of the most commonly used medications to treat lipid disorders and prevent cardiovascular events in high-risk individuals [1] [2] [3] . Similar to other statins, atorvastatin has been associated with the development of skeletal muscle toxicity (myopathy). The severity of the latter can range from myalgia (muscle pain with no evidence of muscle degradation) to the rare but lifethreatening rhabdomyolysis (severe muscle damage potentially accompanied by acute renal failure) [4] [5] [6] [7] [8] . It is widely acknowledged that statin-induced myopathy is a concentration-dependent adverse event and that factors such as increased dose and coadministration of compounds altering statin pharmacokinetics (PK) markedly increase the risk of myopathy [9, 10] . Therefore, an in-depth understanding of atorvastatin PK and the potential effect of clinical, demographic and genetic factors are of significant importance.
Pasanen et al. [14] identified that a well-studied polymorphism (c.521T > C or rs4149056) in the gene coding for the OATP1B1 hepatic uptake transporter (SLCO1B1) increases ATA exposure by 144% in individuals with the homozygous variant genotype (CC) compared with homozygous wild-type individuals (TT). This polymorphic effect is attributed to the decreased hepatic uptake and subsequently metabolism of ATA that leads to higher systemic concentrations. In a different study [15] , a polymorphism (c.421C > A or rs2231142) in the gene coding for the BCRP efflux transporter (ABCG2) was reported to be associated with 72% increased ATA exposure in homozygous variant individuals (AA) compared with wild-type individuals (CC). The increased ATA exposure in the polymorphic patients has been suggested to occur because of decreased efflux on the intestinal wall and subsequently higher bioavailability after oral administration.
Ethnicity has been also identified to play a modulating role in atorvastatin PK as Asian patients have been reported to have significantly higher exposure to ATA compared with Caucasians [16] . This specific ethnic effect has also been observed with respect to other statin acid forms such as rosuvastatin [16, 17] and simvastatin acid [16, 18] . Characteristically, in the USA, the recommended rosuvastatin initial dose in Asians is half of the dose recommended in Caucasians [19] . Available data suggest that this ethnic variability is because of intrinsic rather than extrinsic factors such as environmental factors as it exists even between individuals in the same environment [17, 20] . However, this ethnic variability cannot be fully attributed to differences in the population allele frequencies of the up-to-date known clinically important polymorphisms (e.g. SLCO1B1 c.521T > C, ABCG2 c.421C > A) affecting the PK of statins [16, 18, 19] . It has been proposed that this ethnic effect arises because of lower OATP1B1 hepatic expression in Asians compared with Caucasians irrespective of the SLCO1B1 genotype [19] ; however, recent proteomic findings are contradicting this theory [21] . Understanding the origin of this observed ethnic variability in statin exposure is an area of ongoing research that has received considerable attention lately. However, with the current knowledge, it is very difficult to safely extrapolate atorvastatin PK data and models across ethnic groups (specifically from Caucasians to Asians).
Therefore, the aim of this work is to develop a population PK model for ATA and its pharmacologically active metabolites specifically for the Japanese population, which is, to our knowledge, currently lacking. Subsequently, it is aimed to identify specific single nucleotide polymorphisms (SNPs) that affect the PK of ATA and its active metabolites in this population.
Methods

Description of the available data for model development
The atorvastatin PK data presented in the current work emerged from a clinical trial sponsored by Eli Lilly (Indianapolis, Indiana, USA) that aimed to show the efficacy of LY2484595 either as monotherapy or in combination with atorvastatin in patients with dyslipidaemia. The data reported in the current work are from an arm of this trial in which only atorvastatin was administered to 27 Japanese patients (10 mg orally once daily for 12 weeks). The study protocol was reviewed and approved by ethical review boards (Supplementary data, Supplemental digital content 1, section 1, http://links.lww.com/FPC/B102). The study was carried out in accordance with all applicable regulatory and Good Clinical Practice guidelines and followed the ethical principles originating in the Declaration of Helsinki. All participants signed an informed consent document before participation in the study. Extensive details on the clinical study, such as all the primary and secondary outcome measures, study arms and inclusion/ exclusion criteria, can be found by accessing http://www. ClinicalTrials.gov (study identifier NCT01375075). The individuals studied were not receiving any concomitant medications that could affect the PK of ATA or its major active metabolites (o-OH-ATA and p-OH-ATA). Among all patients, only one had received previous lipid-modifying therapy within the past year before the study and the medication was rosuvastatin tablets 2.5 mg.
Blood samples were collected on four different visits to the clinical research unit and specifically on weeks 2, 4, 8 and 12 since the beginning of the study. To record the time of atorvastatin intake on the day of the PK measurements, participants were instructed not to take the daily dose at home, but at the investigator site. The sampling was sparse in that only two samples were obtained per visit (one predose and one postdose). However, the design of the study was such that the postdose sample was obtained at a different time at every visit to obtain more information on the entire PK profile of the analysed compounds. Illustratively, for a study participant (participant ID: 401), the postdose sample on week 2, 4, 8 and 12 was obtained at 1, 3, 6 and 8 h after dose, respectively. The predose blood samples were drawn to determine trough concentrations of the analysed compounds (the majority of the predose samples were drawn 22-29-h since the last reported dose). Compliance with the required dosing regimen was assessed by direct questioning and by counting the returned study drug. A patient was considered significantly noncompliant if he/she missed more than 7 consecutive days of study medication or more than 16 cumulative days of study medication during the entire study. No patients were significantly noncompliant.
In total, 216 venous blood samples were collected. These samples were drawn into heparin-coated tubes, which were then subsequently used to isolate plasma samples.
Plasma samples were immediately frozen and kept frozen at approximately − 20°C or lower until the time of the assay. Samples were analysed to determine ATA, o-OH-ATA and p-OH-ATA concentrations using a validated LC/MS/MS method (Supplementary data, Supplemental digital content 1, section 2, http://links.lww.com/FPC/ B102). All eight samples from one patient had to be excluded from the PK analysis because of quantification issues.
All the demographic and clinical characteristics of the participants studied are summarized in Table 1 . For the purpose of this work, all the participants studied were retrospectively genotyped for 18 genetic polymorphisms located in seven different genes. More specifically 3, 3, 1, 1, 7, 2 and 1 polymorphisms were genotyped in the ABCB1, ABCG2, CYP3A4, CYP3A5, SLCO1B1, SLCO2B1 and PPARA genes, respectively, as previous literature suggests that all these genes might be implicated in atorvastatin disposition [14, 15, [22] [23] [24] [25] [26] . The distribution of these variants in the studied population is reported in Table 2 . Details of the genotyping and quality control methods are reported in Supplementary data, Supplemental digital content 1, http://links.lww.com/FPC/ B102 (section 3).
Population pharmacokinetic analysis
Population PK modelling was performed using nonlinear mixed-effects modelling software (NONMEM 7.3; ICON Development Solutions, Ellicott City, Maryland, USA) and the first-order conditional estimation method with interaction. Additional investigations of the NONMEM output, statistical and graphical analysis were carried out in Matlab R2014a (The MathWorks Inc., Natick, Massachusetts, USA).
Structural and statistical model
The ATA, o-OH-ATA and p-OH-ATA plasma concentrations available for PK analysis are presented in Fig. 1 . In total, 41/208 (19.7%), 12/208 (5.8%) and 130/208 (62.5%) plasma concentration measurements were below the limit of quantification (BQL) for ATA, o-OH-ATA and p-OH-ATA, respectively. Because of the substantial proportion of BQL data for p-OH-ATA, population modelling of this particular metabolite could not be informed from the available data in this study. A literature search was performed to identify any previous population PK studies in which p-OH-ATA was measured to obtain priors that can support the modelling of this metabolite. In the only (to our knowledge) population PK study that p-OH-ATA was measured, more than 80% of the measurements were BQL and thus, similar to the current study, this metabolite was not modelled [27] . Therefore, population PK modelling was finally pursued only with respect to ATA and its measurable active metabolite o-OH-ATA. As the proportion of BQL data is relatively low for ATA and o-OH-ATA, any such data were treated as missing and were excluded from the analysis [28] . This approach was further validated with the use of a visual predictive check variation in which the agreement between the fraction of observed and modelpredicted BQL concentrations is also examined [29] .
The available ATA and o-OH-ATA plasma concentrations were expressed in their molar equivalents (the molecular weight of ATA and o-OH-ATA is 558.64 and 574.64, respectively) and were log-transformed for simultaneous parentmetabolite modelling. Several structural parent-metabolite PK models were considered including different combinations of one-compartment, two-compartment and three-compartment disposition models for ATA and o-OH-ATA. The elimination of both ATA and o-OH-ATA was assumed to occur from the central compartments. Different simple absorption models were considered (e.g. first-order absorption) as the evaluation of more complex models was constrained by the limited amount of data during the absorption phase of ATA (Fig. 1) . The joint parent-metabolite models are structurally not identifiable as only ATA and o-OH-ATA plasma data after the administration of the parent drug (ATA) are available. Assuming complete conversion of ATA into o-OH-ATA or equal volumes of distribution for the two compounds can resolve identifiability issues, but it would be physiologically invalid and would introduce bias in our results. Therefore, parameter estimation and subsequent covariate analysis were carried out in the domain of the identifiable 'apparent' parameters (Results).
Interindividual variability (IIV) random-effect terms were assigned on model parameters using an exponential relationship. Correlation between the IIV random-effect components was also explored by the incorporation of covariance elements (OMEGA BLOCK option in NONMEM). The incorporation of interoccasion variability (IOV) [30] was also evaluated in model parameters and was retained as long as the objective function and model For the qualitative characteristics, the number of individuals with the characteristic is reported, followed by the percentage in the study population (in parenthesis). For quantitative characteristics, the mean value is reported, followed by the range in the study population (in parenthesis). ALT and AST are liver function tests referring to alanine transaminase and aspartate transaminase, respectively. ALT, alanine transaminase; AST, aspartate transaminase.
diagnostics were improved. Illustratively, IIV and IOV was incorporated into a model parameter y according to Eq. (1):
where θ ij is the parameter estimate referring to the ith individual and the jth occasion (a different visit to the clinical research unit is considered as an occasion),ỹ is the typical population parameter value, η i is the random effect referring to differences between individuals and κ ij is the random effect referring to between-occasion differences within an individual (both η and κ are assumed to be normally distributed with a mean of 0). A common variance was assumed between occasions using the SAME option in OMEGA BLOCK. The residual unexplained variability was modelled for both ATA and o-OH-ATA with an additive error model on the log-transformed data.
Covariate model building
The following population covariates were available and investigated during the covariate model-building procedure: sex, age, height, weight, BMI, alcohol/caffeine/ tobacco products consumption, alanine transaminase and aspartate transaminase liver function tests and genotypes for the 18 SNPs reported in Table 2 . Techniques for the ATA, o-OH-ATA and p-OH-ATA plasma concentration data available for pharmacokinetic analysis. Study participants were on a regimen of 10 mg atorvastatin once daily. The horizontal line represents the limit of quantification. The proportion of data below the limit of quantification (BQL) is also reported for each of the compounds. ATA, atorvastatin acid; o-OH-ATA, ortho-hydroxy-atorvastatin acid; p-OH-ATA, para-hydroxy-atorvastatin acid.
incorporation of multiple SNPs in nonlinear mixed-effects models have been recently proposed and compared [31] including both stepwise forward inclusion-backward elimination procedures [32] and penalized regressions [33] . In this study, the number of tested SNPs is relatively small and a computationally intensive stepwise procedure (extensively described in a previous work [18] ) was used for covariate model building. Briefly, this procedure involves screening of empirical Bayes estimates (given low Z-shrinkage) and a stepwise forward inclusion-backward elimination algorithm that also examines the degree of linkage disequilibrium (LD) between correlated SNPs upon inclusion in each step. Linkage disequilibrium between closely linked SNPs (e.g. the seven SNPs analysed in the SLCO1B1 gene) was assessed in the studied population (with the R 2 metric) and then inspected visually with snp.plotter [34] . The statistical significance threshold was set to 0.05 for the forward inclusion and 0.005 for the backward elimination steps [assessed using a likelihood ratio test (LRT) between the models with or without the covariate]. In addition, as the sample size in the current work is relatively small, a permutation (randomization) testing procedure [35] was used to take into account the possibility of type-I error inflation and correct the LRT significance levels during the backward elimination process (Supplementary data, Supplemental digital content 1, section 4, http://links.lww.com/FPC/B102).
A bootstrapping procedure (n = 1000) was performed with PsN 3.7.6 (Perl-speaks-NONMEM) [36] to evaluate the robustness of parameter estimates and obtain nonparametric 95% confidence intervals (CIs) around these values.
Results
The model that best described the plasma concentrations of both ATA and o-OH-ATA is presented in Fig. 2 . It consists of a first-order absorption process and a onecompartment disposition model for ATA, which is linked through metabolite formation to an additional compartment that describes the disposition of o-OH-ATA. The effect of the rs2622604 genotype (ABCG2 gene) was included in the final model. Specifically, our analysis suggested that individuals carrying one variant allele for this SNP (AG genotype) have 55% higher bioavailability (95% CI: 16-131%) relative to the value in homozygous wild-type individuals (GG). It should be noted that because of the lack of IV data, absolute bioavailability values cannot be determined across the different genotypes and thus covariate effects on bioavailability are manifested/identified in the domain of apparent parameters (e.g. CL ATA /F, V ATA /F). The empirical Bayes estimates of all the apparent parameters that incorporate a bioavailability term (θ 2 -θ 4 , Table 3 ) differed considerably between individuals with the variant (AG) and the wild-type genotype (GG). On the basis of physiological knowledge of the SNP effect (decreased BCRP expression in the intestine; see Discussion), it was interpreted that it is the bioavailability that is affected by this polymorphism rather than the other PK parameters themselves (e.g. CL ATA , V ATA ). Subsequently, a unique covariate effect (θ 6 , Table 3 ) was incorporated into the bioavailability terms of the apparent model parameters, corresponding to the fractional change in oral bioavailability in individuals carrying one variant allele relative to the bioavailability in homozygous wild-type individuals. Inclusion of this covariate effect in the model significantly improved the description of the observed data. The 55% increased bioavailability in the variant genotype individuals yields an equivalent increase in the model-simulated plasma exposures of ATA and o-OH-ATA. A visual predictive check stratified by the rs2622604 genotype is presented in Fig. 6 . It is evident that this BCRP polymorphism increases (on average) the plasma concentrations of both ATA and o-OH-ATA. The developed model that incorporates this SNP effect on atorvastatin bioavailability could adequately describe the observed data and their variability not only in total (Fig. 5 ) but also within each genotype population (Fig. 6 ).
Removal of this SNP effect from the model during the backwards elimination step of the model-building procedure increased the objective function value by 17.46 units, illustrating the importance of this covariate. The permutations-generated empirical distribution of the LRT statistic (change in the objective function value) was used to calculate the corresponding significance level instead of the χ 2 distribution to guard against type-I error inflation. It was evident from the results of the permutation procedure that considerable type-I error inflation can occur in such a small sample size if the LRT statistic is assumed to follow the χ 2 distribution (Fig. 7) . Specifically, the χ 2 probability density is shifted to the left compared with the empirical distribution of the test statistic under the null hypothesis and thus produces consistently lower P-values. Characteristically, the 17.46 units change in the objective function value, when the rs2622604 SNP is removed from the model, corresponds to a P-value of 2.9 × 10 − 5 if the χ 2 distribution is assumed for the LRT statistic. In contrast, using the empirical distribution of the test statistic, the same change in the objective function yields the permutation-corrected P-value (P perm ) of 0.0045, which was the one used to assess the SNP significance. As this value was below the predefined statistical threshold (0.005), the effect of the rs2622604 SNP was retained in the model. This SNP was not identified to have a significant effect on the absorption rate constant (k a ) of the drug. The other two SNPs tested in the ABCG2 gene (rs2231142 and rs4148162) were also not identified to have a significant effect.
The linkage disequilibrium pattern between the seven SNPs tested in the SLCO1B1 gene in the Japanese population studied is shown in Fig. 8 . It was evident that in this population, the rs4149056 SNP is inherited almost independent of the other six SLCO1B1 tested SNPs, whereas the latter are in strong correlation with each other. However, neither rs4149056 nor the other six SNPs were found to significantly affect ATA/o-OH-ATA model parameters in the population studied. Similarly, none of the SNPs tested in the ABCB1, CYP3A4, CYP3A5, PPARA and SLCO2B1 genes or any of the available nongenetic covariates (e.g. age, sex) had a considerable effect on model parameters. Summarizing the covariate model-building procedure, the ABCG2 rs2622604 SNP was the first covariate to be included in the model (as it produced the strongest signal through the initial covariate screening) and afterwards no other covariates achieved the required statistical significance levels for model inclusion.
Discussion
A recent clinical study [16] has shown that Japanese have significantly different atorvastatin PK parameters (area under the curve, C max ) compared with Caucasians. Consequently, previous population PK models for atorvastatin [37, 38] (developed mainly with data from Caucasians) cannot be safely extrapolated in the Japanese population. To our knowledge, the current work is the first to report a population PK model for atorvastatin that specifically focuses on the Japanese population. The fact that the developed model jointly describes the kinetics not only of ATA but also of its active metabolite, o-OH-ATA, is of particular importance in case that investigation of the pharmacodynamic effects is also of interest.
A further aim of this work was to identify genetic covariates that have a considerable impact on atorvastatin PK Covariate effect corresponding to the fractional change in bioavailability (+ 55%) for individuals carrying a variant allele (AG genotype) for the rs2622604 SNP. c Interindividual, interoccasion and residual variability are reported in the domain of the estimated variance terms (ω 2 , π 2 and σ 2 , respectively), followed by the CV%, which was calculated as:
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi ffi ðe variance À1Þ p Â100: in the Japanese population. In contrast to a noncompartmental data analysis approach, the use of nonlinear mixed-effects modelling enables the investigation of genetic effects even when sparse data are available (as in the current study). Additional advantages also arise in a model-based approach such as increased statistical power to detect a genetic effect and improved interpretation of its underlying mechanism [31] . However, with such an approach, adequate study design in terms of sample size and sampling times is crucial.
Our results suggest that a polymorphism (rs2622604) in the ABCG2 gene considerably increases atorvastatin oral bioavailability and subsequently plasma exposure to both ATA and o-OH-ATA. The rs2622604 is an intronic SNP and in-vitro it has been previously identified to decrease BCRP expression in the intestine [39] . This supports the findings of the current study as the lower intestinal BCRP expression in individuals carrying the variant rs2622604 genotype will lead to decreased efflux of the drug back to the intestinal lumen and thus higher bioavailability. This SNP has never been associated before with the PK of atorvastatin or any other statin in vivo. However, it has been repeatedly linked to the PK/pharmacodynamics of compounds used in cancer therapeutics. Specifically, in a previous clinical study, the rs2622604 SNP was associated with irinotecan-induced myelosuppression, proposed to occur as a result of higher levels of the drug in the systemic circulation [40] . In addition, this SNP has been associated with increased plasma exposure to erlotinib [41] and a higher risk for the development of gefitinib-induced [42] and sunitinib [43] -induced toxicity/adverse events. The fact that an association between the rs2622604 genotype and statin kinetics was identified in this work is of particular importance as to date, most of the BCRP-related pharmacogenetic research in this class of drugs focuses on the effects of the c.421C > A polymorphism.
Neither the c.421C > A (ABCG2) nor the c.521T > C (SLCO1B1) polymorphisms were identified to affect Goodness-of-fit plots with respect to the ATA plasma concentration data. DV versus PRED and DV versus IPRED indicate observations versus population and individual predictions, respectively. CWRES versus TIME and CWRES versus PRED indicate conditionally weighted residuals versus time and population predictions, respectively. ATA, atorvastatin acid, Atorvastatin PK in the Japanese population Tsamandouras et al. 33 atorvastatin PK in the current work. The effects of these two polymorphisms on atorvastatin PK have been robustly identified in Caucasian populations [14, 15] and were also recently illustrated in Japanese individuals [16] . It can be hypothesized that the lack of effect in the current work may be because of the small sample size and the complete absence of homozygous variant individuals with respect to these SNPs (Table 2) . Similarly, the effects of two other SNPs that have been of particular clinical interest recently, namely rs35599367 (CYP3A4) and rs4253728 (PPARA) [18, 23, 26] , could not be investigated in the current work as all the individuals studied carried the homozygous wild-type genotype (Table 2) .
Apart from the well-characterized c.521T > C polymorphism, a group of six additional SNPs were also genotyped in the SLCO1B1 gene (rs11045879, rs2291075, rs4149048, rs4149050, rs4149081 and rs4363657). Specifically, three of these SNPs have been associated previously either with altered methotrexate clearance (rs4149081, rs11045879) [44, 45] or with simvastatin-induced myopathy (rs4363657) [46] , and they occur in a much higher frequency in Asian populations compared with Caucasians [47] . Therefore, the reported ethnic variability in statin kinetics could potentially be attributed to the effects of these SNPs. However, these three SNPs are in strong LD with the c.521T > C SNP (rs4149056) in Caucasian populations; thus, it is difficult to identify in-vivo whether they have any additional effects independent of the c.521T > C SNP. In contrast, a completely different LD pattern occurs in the Japanese (Fig. 8) , where all the six SLCO1B1 SNPs reported above are in high LD with each other, but are inherited almost independent of the c.521T > C SNP. Therefore, the independent causal effects of this group of SLCO1B1 SNPs on atorvastatin PK could be investigated in this work. Nevertheless, no evidence of association was observed between the genotypes in this group of six SNPs and atorvastatin PK. Similarly, in our previous study on simvastatin acid PK [18] , a functional effect (independent of the c.521T > C polymorphism) could not be attributed to these SNPs. Taken together, the results of this previous Goodness-of-fit plots with respect to the o-OH-ATA plasma concentration data. DV versus PRED and DV versus IPRED indicate observations versus population and individual predictions, respectively. CWRES versus TIME and CWRES versus PRED indicate conditionally weighted residuals versus time and population predictions, respectively. o-OH-ATA, ortho-hydroxy-atorvastatin acid. Visual predictive check (VPC) of the developed population model for both ATA (left) and o-OH-ATA (right) plasma concentrations. In the upper panels, closed circles represent the observed plasma concentrations (study participants were on a regimen of 10 mg atorvastatin once daily); the areas between the 5th and 95th percentiles of model simulations are shaded, whereas the solid line represents the median of model simulations; the horizontal dashed line represents the limit of quantification. In the lower panels, shaded areas represent the simulation-based 95% confidence intervals for the fraction of model-simulated samples below the limit of quantification (BQL) in each time bin, whereas closed circles represent the actual observed fraction of BQL samples in each time bin. ATA, atorvastatin acid; o-OH-ATA, ortho-hydroxy-atorvastatin acid. Visual predictive check (VPC) of the developed population model stratified by the rs2622604 (ABCG2) genotype. Top and bottom panels refer to ATA and o-OH-ATA, respectively. Left and right panels refer to the wild-type (GG) and the variant genotype (AG), respectively. Closed circles represent the observed plasma concentrations (study participants were on a regimen of 10 mg atorvastatin once daily); the areas between the 5th and 95th percentiles of model simulations are shaded, whereas the solid line represents the median of model simulations; the horizontal dashed line represents the limit of quantification. ATA, atorvastatin acid; o-OH-ATA, ortho-hydroxy-atorvastatin acid.
study and the current work suggest that it is unlikely that these SNPs exert a strong functional effect on the kinetics of OATP1B1-substrates that can possibly explain the ethnic variability reported.
It has been suggested recently that this ethnic variability is more likely to be because of a BCRP-related effect during the absorption process, rather than reduced OATP1B1-mediated hepatic uptake in Asians [16, 21] . It should be clearly noted that the BCRP polymorphism (rs2622604) identified in this work to increase exposure to both atorvastatin and its active metabolite is not expected to explain the observed ethnic variability as it does not have a higher variant allele frequency in Japanese compared with Caucasians [47] . However, this finding clearly highlights the importance of the BCRP transporter on atorvastatin PK in the Japanese population.
The sample size of the current study is one of the main limitations of this work. However, atorvastatin PK data in Japanese dyslipidaemic patients in conjunction with genotypes for several SNPs in different genes implicated in atorvastatin disposition are not readily available in the literature. Therefore, this work aims to expand the current literature knowledge and generate data and hypotheses, which can be valuable for the design of future studies in this population. In addition, only genetic variants that can be supported by previous in-vitro/in-vivo findings were tested in this work and it was our aim to explore SNP effects of large magnitude that may suggest the need for dose adjustment. As the LRT that was used here to detect significant genotype effects is an asymptotic test, considerable type-I error inflation may arise with a small sample size and/or unevenly distributed genotypes [35, 48, 49] . Therefore, a permutation procedure was performed to correct significance levels for type-I error inflation. The fact that the rs2622604 (ABCG2) SNP remains significant even after permutation correction provides additional confidence that it represents a genuine genotype effect and not a spurious association. Future studies are needed that replicate the polymorphic effect identified in this work and also to assess its relevance in other ethnic populations.
The model reported here was adequate for the purpose of investigation (prediction of ATA/o-OH-ATA plasma levels in Japanese individuals with different genotypes); however, its empirical structure and data-driven nature can be considered a limitation. Indicatively, the model does not incorporate any presystemic formation of o-OH-ATA and more importantly does not allow concentration predictions directly at the drug's site of action (liver) or site of toxicity (muscle). The sparsity of the available PK data restricted any attempts to evaluate more complex mechanistic model structures. However, if more data become available in the future, they should be integrated with previous information derived from the physiological understanding of the studied system and in-vitro experiments to develop a mechanistically more sound atorvastatin model as exemplified in recent studies [50] [51] [52] .
Conclusion
In conclusion, here, we presented the first population PK model for atorvastatin that specifically focuses on the Japanese population. The current work reports the identification in this Normalized histogram of the permutations likelihood ratio test statistics (change in the objective function value) for the rs2622604 SNP overlaid with the probability density function of the χ 2 distribution with 1 d.f. (solid line). For the purpose of clarity, the plot specifically focuses on the part of the histogram related to changes in objective function higher than 1.5 units. The insert plot further shows the type-I error inflation as the permutation-corrected P-values (y-axis) are consistently higher than the P-values derived, assuming that the test statistic follows a χ 2 distribution with 1 d.f. (x-axis). OFV, objective function value. Linkage disequilibrium (LD) plot referring to the seven single nucleotide polymorphisms tested in the SLCO1B1 gene in the studied Japanese population.
population of a polymorphism in the ABCG2 gene that considerably increases the exposure to both ATA and its active metabolite o-OH-ATA and that should be a subject of future studies. Taking into account the considerable ethnic variability in atorvastatin kinetics and the fact that elevated systemic drug concentrations may increase the risk of myopathy, it is apparent that this work can be of clinical importance to design future pharmacogenetic studies and guide dosing recommendations tailored specifically for the Japanese population.
